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ABSTRACT : In a series of 38 patients consisting of 13 with overt acute leukemia, 
14 with hypoplastic leukemia, and 11 with myelodysplastic asyndromes (MDS), re-
sponsiveness to low dose cytosine arabinoside (LDAC) regimen was investigated to clarify 
the disease type most benefitted. LDAC was continuously administered intravenously 
at dose 0.2mg/kg/day and continued as long as possible to meet the pre-assigned target 
point of 5% marrow blasts which was confirmed by weekly marrow aspiration. Overall 
response rate was 47%; complete remission (CR) being 31% and partial remission (PR) 
16%. CR rate was significantly different between the disease types ; 69% in hypoplastic 
leukemia, 23% in overt leukemia and 0% in MDS (p=0.01). In hypoplastic leukemia the 
survival time was significantly longer in the LDAC-treated cases compared with 15 
historical control cases treated with supportive care only ; median survial being 750 days 
in the former and 250 days in the latter (p=0.01). In overt leukemia only three M2 AML 
cases obtained CR ; two of them were treated during hypoplastic phase induced by 
intensive chemotherapy. All CR cases eventually achieved the target point after 20 to 
42 days (median 26) of LDAC administration. Substantial toxicity of LDAC was evident, 
but most cases tolerated well. The present investigation suggests that hypoplastic 
leukemia is the disease type most sensitive to LDAC regimen. Stratification of the elderly 
leukemia patients should be considered for this regimen.
       INTRODUCTION 
 Cytosine arabinoside (ara-C) is now widely 
used for a variety of acute leukemias. Con-
ventional dose of ara-C is a major component 
of multi-drug induction chemotherapy for acute 
myeloid leukemias (AML) in most institutions, 
and high dose of ara-C is mainly used for 
post-remission chemotherapy or for induction 
chemotherapy of resistant or refractory
leukemias.' Low dose of ara-C has been so far 
used for the treatment of acute leukemia, 
myelodysplastic syndromes (MDS) or resistant 
leukemia in the elderly and/or compromized 
patients.2-11 
 Bolwell et al recently reviewed the results of 
low dose ara-C (LDAC) regimen reported from 
many institutions.") They reported that overall 
complete remission (CR) rate is around 30% in 
AML and 18% in MDS. These rather low 
unsatisfactory response rates indicate that it is
of clinical importance to clarify whether certain 
type (s) of acute leukemia or MDS show 
preferential response to LDAC regimen. We 
analysed the results of LDAC regimen in a series 
of 38 patients with overt leukemia, hypoplastic 
leukemia, or MDS and concluded that hypo-
plastic leukemia responds best and survival 
time could be durable.
  MATERIALS AND METHODS 
Of twenty-seven cases of acute leukemias 13
had overt acute leukemia defined by FAB 
classification and 14 had hypoplastic leukemia 
defined by histology-proven hypoplastic mar-
row. Hematological profiles of the patients in 
each group are summerized in Table 1 and 3, 
respectively. The reasons of entry to LDAC 
regimen were old age in 11 patients, corn-
promized host in 12 patients and resistant 
leukemia in 4 patients. 
 Diagnosis of hypoplastic leukemia was es-
tablished when the bone marrow clot and/or 
Jamshidi's needle biopsy section shows less
Table 1. Hematological Profiles of Patients with Hypoplasetic Leukemias Treated with LDAC Regimen 
Case Age Sex Peripheral Blood Bone Marrow 
No. Hb(g/dl) WBC(tl) Plt(al) Blast(%) Cellularity(%)' Blast(%) Blast Type' Dysplasia Score' 
 1. 63 M 7.4 2500 42500 1 31 28.0 Ml 2 
 2. 55 F 9.6 3250 244500 0 50 22.4 M4 0 
 3. 58 M 8.3 2050 2500 1 42 28.6 M2 5 
 4. 74 M 3.8 1100 47500 5 44 48.2 L 0 
 5. 70 M 5.9 1700 35500 0 25 18.8 M1 1 
 6. 78 F 6.4 550 7500 2 41 36.0 Ml 4 
 7. 62 F 7.7 1250 65000 0 26 26.0 Ml 0 
 8. 73 M 6.0 1200 31000 0 22 45.1 L 2 
 9. 72 M 9.4 1650 70000 0 34 22.8 Null 4 
 10. 44 M 7.4 800 17500 2 38 56.0 Ml 2 
 11. 76 F 10.7 4500 177500 3 23 20.0 M4 3 
 12. 64 F 6.9 1550 62500 0 22 15.6 M4 5 
 13. 66 M 11.2 2100 62500 0 37 17.0 M2 1 
 14. 56 M 6.4 1300 16000 0 41 42.2 Null 6 
LDAC : low dose cytosine arabinoside, 1, 2 and 3 are all defined in the text
 Table 2. Treatment Outcome in Patients with Hypoplastic Leukemias Treated with LDAC Regimen 
       LDAC Regimen BM Blast(%) PB Neutrophil Count(ul) 
Case Outcome Consolidation duration Survival Remarks 
No. Dose Duration Serum Concept- Before Dayl4 After' Before Nadir After2 Regimen (mo) (mo) 
    (mg/day) (days) ration(ng/ml) 
 1. 10 31 3.96 28.0 16.8 1.6 120 85.5 2686 CR LDAC 5 28 2nd CR 
 2. 10 20 5.31 22.4 10.6 2.4 171 15 3080 CR LDAC 6 26 2nd CR 
 3. 12 25 4.58 28.6 25.2 1.2 823 6.5 1740 CR LDAC 4 17 
 4. 10 42 ND 95.4 82.8 1.0 148.5 68 2150 CR - 12 19 
  5. 13 28 7.67 18.8 28 - 407 0 - ED 3 - - 2 
 6. 10 11 4.21 36.0 22.5 10 346 30 1725 NR - - 10 
 7. 10 24 2.63 26.0 12.5 3.6 231 48 1733 CR BHAC DMP 5 42 2nd/3rd CR 
  8. 10 28 2.75 45.1 12.8 1.8 600 5.5 2525 CR - 9 17 
 9. 10 29 ND 22.8 19.2 3.2 252 31.8 1138.5 NR - - 8 
 10. 10 33 ND 56.0 33 20.8 248 63 144 NR - - 20+ 
 11. 10 21 ND 20.0 2.8 1.0 270 16 1987 CR LDAC 24+ 24+ 
 12. 20 28 ND 22.8 9.2 2.0 564 252 780 CR LDAC 8+ 8+ 
 13. 10 31 ND 17.0 6.8 2.6 546 57 941 CR LDAC 4 6+ 
 14. 12 28 ND 42.2 14.9 4.4 101 0 30 NR - - -
1 : bone marrow blast percent just after the cessation of LDAC in each case. 
2: neutrophil count three weeks after the cessation of LDAC in each case. 
3: early death due to asphyxia.
Table 3. Hematological Profiles and Treatment Outcome in Patients with Overt AML Treated with LDAC Regimen
                            LDAC Regimen Bone Marrow CR 
Case FAB Prior 
No. Age Sex subtype chemotherapy Dose Duration Before After Outcome duration                         (
mg/day) (days) Cellularity' Blast(%) Blast(%) (mo) 
 1. 68 F M2 - 10 14 109 53.4 0.4 CR uncertain 
 2. 50 M M6 - 10 16 92 32 4.4 PR 4 
 3. 68 M M4 - 10 31 583 58.4 10.4 NR 
 4. 73 F M4 DCMP 10 25 386 62 54 NR 
 5. 63 F M4 DCMP 10 21 84 10.4 41.4 NR 
 6. 35 M M3 DCMP 30 17 10 59 98.6 NR 
 7. 69 F ALL VCR+PSL 60 11 29 95.8 81.0 NR 
 8. 32 M ALL VCR+PSL 12 40 5 42.6 12.4 NR 
 9. 23 M Ml - 12 29 39 26.8 22.8 NR 
10. 67 F M2 DCMP 10 21 19 23.6 0.2 CR 13 
11. 59 M M2 DCMP 10 17 17 17.8 0.2 CR 5 
12. 53 M M4 DCMP 10 24 134 25.7 20.8 NR 
13. 41 F M2 DCMP HDAC 10 18 187 8.8 32.8 NR 
1 : nucleated cell count(X 103/1)
than 50% cellular marrow and the blast percent 
exceeds 15% in non-erythroid cells (NEC). Areas 
of cellular marrow was estimated according to 
the method of Hartstock et al.13> Cytological 
types of blast cells in hypoplastic leukemias as 
well as in overt leukemia were determind by 
routine cytochemistry and immuno-phenotyping 
including terminal deoxynucleotidyl transterase 
(TdT). Types of hypoplastic leukemia was 
classified according to leukemic cell characters 
defined as follow ; peroxidase(PO)-positive my-
eloblasts without maturation as M1, PO-positive 
myeloblasts with maturation beyond prom-
yelocytes as M2, PO-positive as well as non-
specific esterase positive blasts and myelomo-
nocytic components as M4, PO-negative/ 
TdT-positive blasts as L and PO-negative/ 
TdT-negative blats as Null. The latter two 
categories were negative for common ALL 
antigen. 
 Since some cases of the above-defined hy-
poplastic leukemias had tri-lineage dysplasia in 
mature cell fractions of the bone marrow, the 
degree of morphological dysplasia was graded 
into three scores ; score 1 for less than 5% 
dysplastic cells in each cell lineage, score 2 for 
5-20% and score 3 for 20% or more. Sum of the 
scores for three lineages was considered the 
dysplasia score for a given case. 
 In order to evaluate clinical benefit from 
LDAC regimen in patients with hypoplastic 
leukemia, 16 historical control cases with this
disease which were treated with supportive 
cares only were also analysed. Clinical and 
hematological features of the hypoplastic 
leukemia patients totaling 29 cases in number 
are summarized in Table 7. 
 Eleven cases of FAB-defined MDS were 
composed of six patients with refractory ane-
mia with excess of blasts in transformation 
(RAEB-T) and two with RAEB, two with 
refractory anemia (RA) and one with RA with 
ringed sideroblasts (RARS). Hematological pro-
file of the patients was summarized in Table 
4. 
 Ara-C was continuously administerred at dose 
0.2mg/kg/day by using an intravenous infusion 
pump (Terumo) or via a hyperalimentation 
catheter. Duration of treatment wes determined 
primarily by the blast percent in the bone 
marrow and performance state of individual 
cases. 5% blast cells was assigned as target 
point of successful cytoreduction by LDAC. 
Patients who obtained complete remission (CR) 
was given two or three courses of 21 days' LDAC 
regimen or BHAC-DMP14) (behenoyl ara-C + 
daunomycin + 6-mercaptepurine and predni-
solone) as conslidation therapy. The plasma 
concentration of ara-C was measured by an 
redioimmunoassay in seven cases of hypoplastic 
leukemia on day 4 of LDAC regimen according 
to the pharmacokinetic results obtained by 
Kreis et al.1° 
 In this study CR from leukemias or MDS was
Table 4. Hematological Profils and Treatment Outcome in Patients with MDS Treated with LDAC Regimen
                       Peripheral Blood Bone Marrow LDAC Regimen 
Case A
ge Sex FAB Outcome Survival No. subtype Hb WBC Plt Blast Cellu- Blast Auer Dose Duration (mo)                 (
g/dl) (ul) (,ul) (%) larity' (%) body (mg/day) (days) 
 1. 64 M RAEB-T 5.7 3700 3.5 1 105 16.4 + 20 26 NR 7 
 2. 50 M RAEB 5.0 2200 0.6 1 101 5.0 - 12 10 PR 24+ 
 3. 81 F RAEB 7.3 4600 2.9 0 135 9.6 - 10 14 PR 3 
 4. 77 M RAEB-T 6.4 1700 3.1 4 165 12.2 + 10 21 AML 7 
 5. 36 M RAEB-T 5.8 2350 0.25 6 159 13.8 + 10 28 AML 4 
 6. 36 F RAEB-T 5.9 7750 24.5 13 86 24.0 - 10 28 PR-AML 30+ 
 7. 54 M RAEB-T 5.5 3400 6.0 3 211 21.0 - 12 23 ED 4 
 8. 42 M RAEB-T 7.0 2500 15.0 5 440 21.0 - 16 18 NR 5 + 
 9. 71 F RA 6.2 3800 3.0 0 176 1.0 - 8 15 NR 6+ 
10. 59 M RA 5.8 4200 6.0 0 187 2.0 - 10 14 PR 16+ 
11. 77 F RARS 6.1 3800 15.0 0 258 1.0 - 10 14 PR 44 
1 : nucleated cell count (X 109/l), ED : early death
defined as the hematological state characterized 
by normalization of leukocyte count, neutrophil 
percent and platelet count and less than 5% 
marrow blasts and partial remission (PR) as the 
state with normal blood parameters but 5% or 
more marrow blasts in case of leukemias and 
3g or more Hb increment and two-fold or more 
increment in neutrophil and/or platelet count 
in case of MDS. Statistical analysis was 
performed by using Kaplan-Meyer's method and 
Fischer's exact test.
          RESULTS 
Response Rates according to Disease Groups 
 Overall respones rate was 47% in this series; 
CR being 31% and PR 16%. CR rates were 
significantly different among disease groups ; 
69% in hypoplasetic leukemia, 23% in overt 
leukemia and 0% in MDS (p=0.01). PR was 
obtained in one case of overt leukemias and in 
five cases (45%) of MDS. 
Response in Hypoplastic Leukemia 
(a) Response Pattern 
 All of nine CR cases were treated for 20 days 
or more (20-42 days). Six of them showed a 
significant reduction of the blast percentage in 
day-14 bone marrow by more than 50% of 
pre-treatment value. In the remaining three 
cases the blast percent eventually decreased on 
day-25, 29 and 42, respectively. In all CR cases
the final blast percent was below the target point 
of 5%. Case 5 died of asphyxia when his 
peripheral blood began to show neutrophil 
recovery. In Case 11 ara-C was discontinued 
on day 12 due to pneumonia complicating early 
induction. 
 The median nadir neutrophil count was 40/,ul. 
The neutrophil count began to increase before 
cessation, of LDAC regimen in three CR cases 
and within 14 days after the regimen in six cases. 
 Seven CR cases received consolidation 
therapy ; LDAC was repeated in six cases, and 
BHAC-DMP was given in one case. The median 
CR duration was 6 months. All CR cases 
eventually relapsed showing again hypoplastic 
bone marrow manifestation. The second CR 
was obtained with LDAC regimen again in three 
cases and the third CR in one. 
 The median serum ara-C concentration was 
4.4 ng/ml in seven cases of MDS measured. 
Unfortunately ara-C concentration was not 
measured in cases with overt lenkemia or MDS. 
(b) Treatment Outcome in relation to His-
tological and Cytological Features (Table 5) 
 Cases of hypoplastic leukemia were devided 
into two groups according to severity of bone 
marrow hypoplasia ; severely hypoplastic group 
with less than 30% cellular marrow and mildly 
hypoplastic group with30-50% cellular marrow. 
CR rate was significantly higher in the former 
(P=0.01). 
 Cases were also devided into severly 
dysplastic group with score 4 or more and
Table 5. Treatment Outcome in Relation to Histological and Cytological Features (Hypoplastic Leukemias)
         BM Cellularity I)ysplasia Blast Types 
         >_30% 30< <50% Score 0^-3 Score 4-9 M1 M2 M4 Null Lymphoid 
Case No (%) 5(100) 9(100) 7(100) 6(100) 5(100) 2(100) 3(100) 2(100) 2(100) 
CR (%) 4( 80) 5( 56) 6( 86) 3( 50) 2( 40) 2(100) 3(100) 0( 0) 2(100) 
NR (%) 1( 20) 4( 44) 1( 14) 3( 50) 3( 60) 0( 0) 0( 0) 2(100) 0( 0)
Table 6. Comparison of Clinical and Hematolo-
        gical Features between Responders and 
        Nonresponders (Hypoplastic Leukemias)
                 CR NR 
Case No. 9 4 
mean age 65.7 62.5 
PB 
 WBC (MI) 2005 1075 
 Hb (g/dl) 80 7.4 
 Plt (x 104/,u l) 8.4 2.8 
 lymphocyte (%) 52 63.3 
BM 
 Blast(%)/ANC 27.7 37.2 
 Blast(%)/NEC 34.7 46.6 
 lymphocyte (%) 27.3 19.2 
 G+E (%) 35.2 38.9 
 mean survival (mo) 20.7* 10.0*
* : statistically significant(p<0 .05) 
case 5 of early death excluded from this table.
Fig. 1. Comparison of Survival between LDAC-
      treated Group and Historical Control
minimally dysplastic group with score 0 to 3. 
Significantly higher CR rate was noted in the 
minimally dysplastic groups (p=0.01). 
 CR rates in Null type and Ml-type cases were 
lower than those in M2-type, M4-type and L-type 
cases. These differences were not significant 
due to the small case number in each type. 
(c) Comparison of Clinical and Hematological 
Parameters between Responders and Non-
Responders. 
 As shown in Table 6 responders revealed 
higher leukocyte count, Hb value and platelet 
count on initial diagnosis. The bone marrow 
blast percent was lower in the responders. 
These differences were not statistically 
significant. Survival time was significantly 
longer in the former (p=0.03). 
(d) Comparison of Survival Time between 
LDAC-treated Group and Historical Control 
Group. 
 As shown in Fig. 1, survival time was 
significantly longer in the LDAC-treated group; 
50% survival being about 250 days in the 
historical control group and 750 days in the 
LDAC-treated group. In the latter group four 
cases survived for more than two years as the 
result of continued first CR in one case and 
repeated achievement of CR in three cases. 
Response in Overt Acute Leukemia Group 
 Three cases obtained CR ; all being FAB M2 
type AML. In two of them LDAC was started 
during hypoplastic phase induced by the 
intensive multi-drug chemotherapy which failed 
to erradicate leukemic blasts efficiently. CR 
duration was not so durable. In two ALL cases 
LDAC was also given during hypoplastic phase 
after vincristine/prednisolone therapy. How-
ever, lymphoblasts which were common ALL 
antigen positive were resistant to this regimen. 
Response in MDS Group 
 PR was obtained Only in five of 11 cases 
treated. In Case 2 PR was obtained after a 
severe bone marrow aplasia induced by a short 
LDAC course of 10 days. PR in this case was 
durable for one year and morphological 
dysplastic chaneges were reduced in degree. PR
states in other cases was brief ; soon leading 
to overt AML in one case.
         DISCUSSION 
 The overall CR rate of 34% in acute leukemia 
of the present series is very similar to that 
reviewed by Bolwell.12) However, we noticed 
that CR cases were apparently concentrated in 
the hypoplastic leukemia group ; CR rate 
reaching nearly 70%. Although entry of cases 
to the present series was not completely 
sequential, the hypoplastic leukemia seems to 
be the best candidate for this regimen. Other 
reports also pointed out the better effect of 
LDAC on the hypoplastic leukemia.' 16) Among 
overt AML cases only three patients with M2 
enterred CR in this series. In two of them the 
regimen was started when the bone marrow was 
still hypoplastic but with significant number of 
leukemic blasts remaining after multi-drug 
induction therapy. Thus the hypoplastic 
marrow which indicates smaller leukemic cell 
burden seems to be prerequisite for good 
outcome by LDAC regimen. It is possible that 
LDAC cannot exert cytotoxic effect efficiently 
in cases with overt AML or larger leukemic cell 
burden. In the present series ara-C was 
continuously infused intravenously and the 
median concentration was 4.4ng/ml on day 4. 
This concentration is apparently within the 
range of ara-C cytotoxicity measured in vitro 
on fresh AML cells but such a low concentration 
cannnot cover whole range of AML blast cell 
growth. Our study, therefore, suggests that 
sensitivity to LDAC of leukemic blasts as well 
as smaller leukemic burden primarily determine 
the treatment outcome. 
 The long-term admistration of ara-C may be 
another important factor determing the 
outcome. In our series the administration period 
was determined by serial bone marrow 
examination (mostly weekly interval) to meet the 
target point of 5% blasts. In the hypoplastic 
leukemia this was achieved by the median of 
26 days' infusion of ara-C. During this preiod 
neutrophil count in the peripheral blood 
declined progressively but never disappeared in 
most cases. Most patients tolerateted well this 
neutropenic phase with supportive cares
Table 7. Clinical and Hematological Features of 29 
        Patients with Hypoplastic Leukemias
                          mean value (range) 
Age 63.5 (44^-84) 
male/female 18/11 
PB 
 WBC (,ul) 2081 (550-4500) 
 Hb (g/dl) 7.7 (3.1-13.2) 
 plt (X 104/ul) 7.1 (0.75-26.25) 
 lymphocyte (%) 63.9 (15--94) 
 Blast(+) Case 14 (48%) 
 Blast(%) in positive cases 2.0 (1^-7) 
BM 
 Cellularity 
    <_30% 10 cases (42%) 
  30< <50% 14 cases (58%) 
 Blast(%)/ANC 29.2 (9.8-56) 
 Blast(%)/NEC 37.1 (17.9^-63.3) 
 Blast Type (cases) 
   M1 13 cases (44%) 
   M2 6 cases (21%) 
   M4 4 cases (14%) 
   Null 4 cases (14%) 
   Lymphoid 2 cases (7%) 
 Dysplasia Score 
   0^-3 18 cases (62%) 
   4-9 11 cases (38%) 
 G+E (%) 36.1 (4.8-74) 
 lymphocyte (%) 28.5 (7.6-55)
including prophylactic antibiotics, transfusion 
of red cells and platelets and intravenous 
hyperalimentation in some compromized hosts. 
The serial marrow examinations disclosed early 
or late decline of the blast percent in most CR 
cases. This decline was absent or inadequate 
in cases who failed to obtain CR. It was 
suggested that less than 5% bone marrow blasts 
is crucial to obtain CR. Although many trials 
of LDAC used 14 to 21 days as intended duration 
of treatment, our study suggests that admin-
istration of LDAC should be continued long 
enough to achieve the target in individual cases. 
As shown in Table 7 in most cases of hypoplastic 
leukemia the blast percent is less than 50% and 
the blast cells usually do not show rapid 
increase. These biological characteristics 
suggest rather low growth rate of leukemic cells. 
LDAC regimen which continues over three to 
six weeks may cover efficently the cell cycle of 
slow growing leukemic cells so that eventual 
cytotoxic effect ensues. 
 In the present series FAB-defined MDS group
showed the worst response rate which is 
compatible with that in Bolwell's review, 
although other reports obtained higher CR 
rate.17" 161 Some cases of the hypoplastic 
leukemia group have severe tri-lineage dysplasia 
in the mature bone marrow cells suggesting 
common biological features shared by MDS 
group. We compared the response rate between 
the two morphologically distinguished groups, 
ie, minimally dysplastic group and severely 
dysplastic group. The response rate was 
significantly lower in the severely dysplastic 
group. However, this rate is still much higher 
than that in MDS group. Therefore, the marrow 
hypocellularity seems more important than the 
mere presence of dysplasia in determining good 
outcome with LDAC regimen. Howe et al also 
considered that the hypoplastic leukemia is a 
disease entity distinct from MDS, especially 
RAEB or RAEB-T, of which marrow is usually 
normo-or hypercellular.19) 
 Although early works with LDAC regimen 
suggested that ara-C exerted its effect by 
inducing differentiation of leukemic blast 
cells,',', 20, 21, 22) later works mostly favoured 
cytotoxic effect as major mechanism of CR 
induction based on the regular observation of 
aplastic bone marrow before CR. In the present 
series all cases which eventually enterred CR 
passed through an apparent aplastic phase 
irrespective of disease group. In a few CR cases 
granulopoiesis began to recover in the periph-
eral blood before t t t t rore cessation of L r t' nD Ci.. This can 
be explaind by clonal change achieved by 
cytotoxic effects of ara-C on leukemic blasts 
and relative resistance of residual normal 
hematopoietic precursors to low serum con-
centration of ara-C. Several studies including 
our own using cytogenetic marker and/or in 
vitro clonal culture confirmend such a clonal 
change.", 23,24,21) On the contrary there is few 
study comfirming the differentiation induction 
by ara-C that can be seen easily in leukemic 
cell lines cultured in vitro .261 The relative 
resistance of normal myeloid precursors to low 
ara-C concentration was suggested by our 
observation that normal CFU-GM persistently 
developed GM-colonies during consolidation 
therapy with LDAC (data not shown). 
 Proportion of the elderly patients among the
total acute leukemia patients seems to be 
expanding these years in most countries. Some 
reports insist that intensive multi-drug 
chemotherapy can exert substantial CR rate 
comparable to that in younger age group. 19,27) 
However, it is usually difficult to reproduce such 
a good outcome. Therefore, treatment strategy 
is still controverial concerning chemotherapy of 
acute leukemia in the elderly. If we could have 
a mild chemotherapy regimen which exerts 
effective and even selective cytotoxicity on 
leukemic blasts, but maintan patient's condition 
well, a great improvement in the cutcome of 
these patients can be obtained. As shown in 
the present series by comparing the results with 
historical control cases of hypoplastic leukemia 
which were treated with supportive cares only, 
apparent improvement in survival time was 
observed. The finding that four cases survived 
for more that two years by obtaining a long CR 
or repeated CRs with this regimen strongly 
suggests a real benefit from LDAC regimen for 
the elderly patients with hypoplastic leukemia. 
With conventional supportive cares only these 
patients usually show median survival of 
around 8 to 10 months. 19, 28, 29, 30) In our instituion 
this type of leukemia comprises almost 50 
percent of the leukemia in the elderly. 
Unfortunately overt leukemias in the elderly 
seem less sensitive to this regimen. Therefore, 
it is of clinical importance to stratify elderly 
patients with acute leukemia according to the 
histoiogically-determined bone marrow cellu-
larity. 
 In most CR cases the duration of CR induced 
by LDAC was rather short, around six months 
in this series as well as in other reports. We 
are now giving CR cases the same LDAC 
regimen or multi-drug intensive chemotherapy 
as consolidation chemotherapy. So far there is 
no convincing result that these consolidations 
prolong CR duration (data not shown). 
Therefore, it is urgently necessary to develop 
a new combination regimen in order to obtain 
durable CR by incorporating newer drugs such 
as mitoxantrone, VP-16 or aclarubicin to LDAC. 
Such a new approach should be also tested for 
overt leukemias in the elderly or compromized 
patients.
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